Welcome
Welcome to Heather's Hope, your monthly digest of breakthrough research, clinical innovations, and advances in pancreatic cancer treatment and detection. This month brought significant momentum as the research community continues to push boundaries and offer new hope to patients and their families. November also marked Pancreatic Cancer Awareness Month, with World Pancreatic Cancer Day celebrated on November 20th under the theme "Shine a Light: Early Detection Saves Lives."
THE MONTH IN NUMBERS
67,440 estimated new pancreatic cancer diagnoses in the U.S. in 2025
51,980 estimated deaths from pancreatic cancer in 2025
13% five-year survival rate for pancreatic cancer currently
2030 projected year pancreatic cancer becomes the 2nd leading cause of cancer death in the U.S.
BREAKTHROUGH DISCOVERIES
1. Novel Antibody Therapy "Wakes Up" the Immune System
The Discovery: Northwestern Medicine scientists have uncovered how pancreatic tumors evade the immune system and developed a groundbreaking antibody therapy to counter this evasion strategy.
What's Happening: Pancreatic tumors exploit a natural safety mechanism by coating themselves with a sugar called sialic acid on a surface protein called integrin α3β1. This sugar disguise sends a false "don't attack" signal to immune cells through a sensor called Siglec-10. The team developed monoclonal antibodies that block this sugar-mediated signal, essentially unmasking the tumor's disguise.
Preclinical Results: In mouse models, the antibody therapy successfully reawakened immune cells to attack cancer cells. Tumors in treated mice grew significantly slower than in untreated controls—a major breakthrough after six years of research.
Next Steps: The team is now refining the antibody for human use and plans to:
Conduct early safety and dosing studies
Test combinations with current chemotherapy and immunotherapy
Develop a companion diagnostic test to identify which patients' tumors rely on this sugar-based pathway
Timeline: Dr. Mohamed Abdel-Mohsen estimates this therapy could reach patients in approximately five years if progress continues as planned.
Our Perspective: This represents a paradigm shift in understanding pancreatic cancer's immune resistance—one of the field's most persistent challenges.
2. PI3K-C2Y Protein Identified as Tumor Suppressor
The Research: Scientists at Worldwide Cancer Research in Italy have identified PI3K-C2Y, a protein that may function as a tumor suppressor in pancreatic ductal adenocarcinoma (PDAC).
Key Finding: Counterintuitively, tumors actually grow faster without the PI3K-C2Y protein, suggesting it acts as a critical "stop signal" to cancer cell growth. This discovery opens entirely new therapeutic avenues.
Significance: Understanding how this protein suppresses tumor development could pave the way for new pancreatic cancer therapies targeting this mechanism.
Future Direction: This work suggests potential for therapies that enhance or mimic the tumor-suppressing function of PI3K-C2Y.
3. Novel Nanoparticle Therapy Shows Dramatic Results
The Technology: Researchers at Sylvester Comprehensive Cancer Center, the University of Miami College of Engineering, Moffitt Cancer Center, and Cellular Nanomed, Inc. have developed magnetoelectric nanoparticles (MENPs) that can locate and destroy pancreatic tumors.
How It Works:
MENPs are injected intravenously and guided to the tumor site using a small magnet
Inside an MRI scanner, a magnetic field activates the particles
The activated particles generate tiny electric fields that disrupt cancer cell membranes
This triggers natural cell death (apoptosis) while leaving healthy tissue unharmed
Preclinical Results:
Tumors shrank to one-third their original size
Complete tumor disappearance in one-third of treated models
Survival time more than doubled
No damage to healthy organs
Advantages:
No drugs, heat, or invasive procedures required
Minimizes side effects
Could overcome limitations of existing electric-field therapies
Significance: Dr. John Michael Bryant notes this approach "brings a new dimension to theranostic oncology by coupling imaging and controlled physical mechanisms of tumor treatment in real time."
Clinical Path: While currently at the preclinical stage, successful translation to humans could revolutionize pancreatic cancer treatment.
4. Early Detection Tool: PACMANN Blood Test Updates
The Tool: The PAC-MANN test (Protease Activity-Based Assay using a Magnetic Nanosensor) continues to demonstrate promise for early pancreatic cancer detection.
Performance Metrics:
98% accuracy at distinguishing pancreatic cancer patients from healthy individuals and those with non-cancerous pancreatic issues
85% accuracy for early-stage cancer detection when combined with the established CA 19-9 test
Quick fluorescent readout requiring only a tiny blood sample
Monitoring Capability: The test can also track treatment effectiveness—researchers observed decreased protease activity after surgery, suggesting it can monitor therapeutic response in real-time.
Significance: Early detection could increase survival rates to over 80%, making this test a potential game-changer in pancreatic cancer care.
5. Stool Microbiome Testing for Early Detection
The Innovation: Worldwide Cancer Research scientists have discovered that analyzing microorganisms (bacteria) in stool samples could provide a fast, non-invasive method to detect and diagnose pancreatic cancer early.
Why This Matters: Given the difficulty of early pancreatic cancer detection, a simple stool-based test could be transformative for prevention and early intervention strategies.
Potential Impact: This screening approach could be a game-changer in preventing deaths from this lethal cancer type.
CLINICAL TRIAL ADVANCES
Pelareorep Phase 3 Trial Gets FDA Green Light
The Breakthrough: Oncolytics Biotech announced FDA alignment on the Phase 3 trial design for pelareorep, an oncolytic virus designed to prime the immune system against pancreatic tumors.
Trial Design:
First-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC)
Three-arm comparison:Gemcitabine + nab-paclitaxel (standard chemotherapy)
Gemcitabine + nab-paclitaxel + pelareorep
Gemcitabine + nab-paclitaxel + pelareorep + checkpoint inhibitor
Primary endpoint: Overall Survival (OS)
Interim efficacy analysis planned for early benefit assessment
Historical Context: Post-hoc analysis showed pelareorep + chemotherapy achieved approximately 22% two-year survival rate versus 9% with chemotherapy alone (historical benchmark).
Significance: This could become the first approved immunotherapy for first-line pancreatic cancer—a transformative milestone.
Next Steps: Oncolytics is completing administrative preparations including protocol finalization, supporting documentation, and site selection. The company is also actively pursuing strategic partnerships.
CAR-NKT Cell Therapy Shows Remarkable Efficacy
The Innovation: UCLA researchers have developed a CAR-NKT cell therapy (Chimeric Antigen Receptor Natural Killer T cell therapy) that demonstrates superiority over current immunotherapies in pancreatic cancer models.
Key Advantages:
Mass-producible and storage-ready: Unlike personalized CAR-T therapies requiring weeks to manufacture, this can be produced in bulk and stored for immediate use
Cost-effective: Available at a fraction of the cost of current cell therapies
Highly effective tumor-homing: Cells express high levels of chemokine receptors that function as "molecular GPS systems," actively seeking tumors regardless of location
Preclinical Performance:
Tested across multiple pancreatic cancer models (in-pancreas tumors, metastatic tumors, subcutaneous tumors)
Consistently slowed tumor growth and extended survival
Maintained cancer-killing potency in harsh tumor environments
Showed minimal signs of exhaustion (a common problem with other cell therapies)
Clinical Path: With all preclinical studies now complete, the team is preparing FDA applications to begin clinical trials.
Our Perspective: This "one-product-fits-all" approach could democratize advanced immunotherapy access for pancreatic cancer patients.
Daraxonrasib (RAS Inhibitor) Advances in Development
The Progress: The FDA granted orphan drug designation to daraxonrasib (RMC-6236), a multiselective RAS(ON) inhibitor targeting KRAS mutations—present in approximately 95% of pancreatic cancers.
Clinical Data from Phase 1/1b:
In KRAS G12X-mutant populations: 36% objective response rate
Across broader RAS-mutant populations: 27% objective response rate
Median progression-free survival: 8.8 months (KRAS G12X-mutants)
Disease control rates: 91-95%
Median overall survival: 13.1-15.6 months
RASolute Phase 3 Trial: A global three-arm Phase 3 trial is scheduled to begin in Q4 2025 (RASolute 303), testing:
Daraxonrasib monotherapy
Daraxonrasib vs. standard second-line chemotherapy
Enrollment in previously treated metastatic PDAC patients
Significance: The RAS-targeting revolution represents one of the biggest therapeutic advances in pancreatic cancer history, with daraxonrasib positioned as a potential second-line standard of care.
Timeline: Expected completion by December 2027.
Atebimetinib Shows Promise in First-Line Treatment
The Data: Early nine-month follow-up data from a clinical trial demonstrates that atebimetinib (IMM-1-104), combined with modified gemcitabine/nab-paclitaxel, significantly improves pancreatic cancer survival rates.
Clinical Benefits:
Improved overall survival
Enhanced progression-free survival
Improved tolerability compared to chemotherapy alone
Durable response noted in patient populations
Physician Perspective: Dr. Barbara Ma reports: "I have seen firsthand in my own patients the benefits of atebimetinib's durability and tolerability. The remarkable overall survival, progression-free survival, and tolerability data represent an important step towards creating urgently needed new options for these patients."
Next Steps: A confirmatory study is being planned to validate these promising early results.
RESEARCH MOMENTUM
Three Key Research Directions Highlighted
During Pancreatic Cancer Awareness Month, Dana-Farber Cancer Institute highlighted three critical research advances:
1. Earlier Detection Innovation
AI and biomarker tools being developed for improved screening
PAC-MANN and microbiome testing represent paradigm shifts in detection methodology
2. RAS Therapeutics Revolution
Multiple RAS-targeting therapies in clinical trials
Daraxonrasib Phase 3 study underway
Approximately 90% of patients in Phase 1 daraxonrasib trials showed some benefit
Could provide foundation for more effective combination therapies
3. Novel Immunotherapy Development
Sugar-based immune evasion mechanism discovered and targeted
CAR-NKT cell therapy showing remarkable results
Multiple vaccine approaches in trials (mRNA-based, neoantigen-targeted, KRAS-directed)
AWARENESS MONTH IMPACT
November 2025: Pancreatic Cancer Awareness Month Recap
What Happened:
Landmarks worldwide lit up in purple (pancreatic cancer awareness color)
Survivor and caregiver stories elevated public awareness
Genetic counseling initiatives promoted for at-risk individuals
Advocacy efforts focused on increased research funding
Key Messages Shared:
Early detection could increase survival rates to over 80% (compared to current 13% five-year survival)
Approximately 67,440 new diagnoses expected in 2025
Prevention through healthy habits: tobacco avoidance, weight management, diabetes control
WHAT THIS MEANS FOR PATIENTS & FAMILIES
Reasons for Hope
Immune evasion mechanism now understood: The sugar-coat trick can be targeted—offering potential new therapeutic approaches
Multiple pathways being addressed:
RAS mutation targeting (present in 95% of pancreatic cancers)
Immune system reactivation
Early detection breakthroughs
Novel cell therapy platforms
Clinical trials expanding:
First-line immunotherapy options emerging
Precision medicine approaches advancing
Less toxic alternatives to traditional chemotherapy being developed
Detection improving: New blood tests and biomarker approaches could catch cancers earlier when treatment is more effective
For Patients & Families
Consider these action items:
Discuss genetic counseling if you have a family history of pancreatic cancer
Talk to your healthcare provider about early detection options if at risk
Ask about participation in clinical trials—multiple options now available
Stay informed about emerging therapies through trusted sources like PanCAN, AACR, and your oncology team
LOOKING AHEAD TO DECEMBER
Ongoing Phase 3 trial preparations and patient enrollment
FDA meetings and regulatory approvals expected
Holiday fundraising campaigns supporting pancreatic cancer research
Year-end research summaries and 2026 outlook publications
RESOURCE CORNER
For More Information:
Pancreatic Cancer Action Network (PanCAN): www.pancan.org
American Association for Cancer Research (AACR): www.aacr.org
National Cancer Institute (NCI): www.cancer.gov
Clinical Trials: www.clinicaltrials.gov
Pancreatic Cancer Facts:
It is the third leading cause of cancer death in the U.S.
Projected to become the second leading cause by 2030
Five-year survival rate: 13% (compared to 90%+ for some other cancers)
Early detection could increase survival to over 80%
FINAL THOUGHTS
November 2025 has been a month of genuine scientific breakthrough and renewed hope. From discovering how tumors hide from the immune system to engineering next-generation cell therapies, the pancreatic cancer research community is accelerating progress across multiple fronts. While challenges remain, the convergence of early detection innovations, precision medicine approaches, and novel immunotherapies suggests we are entering a transformative era in pancreatic cancer care.
The message is clear: Early detection saves lives, awareness fosters hope, and collective engagement paves the way for breakthroughs.
Heather's Hope is committed to bringing you the most significant advances in pancreatic cancer research and treatment each month. We hope this newsletter provides both information and encouragement as we continue the mission of improving outcomes for pancreatic cancer patients worldwide.
Have a story to share? Know of an advance we missed? Contact us to be featured in next month's newsletter.